<DOC>
	<DOCNO>NCT01241435</DOCNO>
	<brief_summary>The purpose study evaluate effect liver function much study drug ( LY2216684 ) get blood stream long take body get rid . Information side effect may occur also collect . The duration participation study approximately 12 day include screen visit . This study require 1 clinic confinement 5 days/4 night follow 1 outpatient follow-up visit . A screening visit require within 30 day prior start study . This research study open label study . The study involve single oral dose 18 mg LY2216684 give 2 tablet .</brief_summary>
	<brief_title>A Study LY2216684 Subjects With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Male subject : Agree use reliable method birth control study 3 month follow last dose study drug . Female subject : Are woman childbearing potential test negative pregnancy time enrollment , use reliable method birth control 6 week prior administration study drug , agree use reliable method birth control study 1 month follow last dose study drug ; Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause ( least 1 year without menses 6 month without menses follicle stimulate hormone [ FSH ] level great equal 40 mIU/mL ) . Have Body Mass Index ( BMI ) 17.0 35.0 kg/m2 , inclusive , screen . Have acceptable blood pressure pulse rate ( sit ) , determine investigator . Have venous access sufficient allow blood sample per protocol . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Lilly institutional review board ( IRB ) govern site . Control Subjects : Are overtly healthy , determined medical history physical examination . Have clinical laboratory test result within normal reference range investigative site result acceptable deviation , judge clinically significant investigator , time screen . Subjects Mild , Moderate , Severe Hepatic Impairment : Subjects stable liver disease ( alcoholic liver disease , posthepatitis , biliary cirrhosis , cryptogenic ) classify ChildPugh score A , B , C ( Pugh et al . 1973 ) . Clinical laboratory test result deviation judge investigator compatible hepatic impairment subject , additional clinical significance study . All subject : Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device study drug use study , concurrently enrol type medical research judge scientifically medically compatible study . Have know allergy LY2216684 relate compound . Are person previously complete withdrawn study study investigate LY2216684 past 6 month screen . Have ECG reading consider clinically significant investigator , history significant cardiac dysrhythmia conduction defect , opinion investigator , increase risk associate participate study . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . There evidence history neurological disease transient ischemic attack , stroke , syncope episode , encephalitis , meningitis , except subject liver diseaserelated encephalopathy may allow . Presence acute infection fever . Are woman positive pregnancy test woman lactate . Have lose 500 mL blood 3 month prior study entry . Are subject average weekly alcohol intake exceed 21 unit per week , subject unwilling adhere restriction study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Are subject unwilling adhere study caffeine restriction . Are subject unwilling abide smoke restriction resident clinical research unit ( CRU ) . Have document suspected history glaucoma . Control Subjects : Have significant active hematological disease , history significant active bleeding , coagulation disorder . Use intend use overthecounter ( include vitamins/mineral supplement , herbal medicine ) prescription medication 14 day , prior enrollment study . Have history presence cardiovascular , respiratory , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism elimination drug constitute risk take study medication interfere interpretation data . Regularly use know drug abuse and/or show positive finding urinary drug screening . Evidence hepatitis C and/or positive hepatitis C antibody . Evidence hepatitis B and/or positive hepatitis B surface antigen . Show evidence significant active neuropsychiatric disease . Subjects Mild , Moderate , Severe Hepatic Impairment : Evidence significant active disease responsible associate liver impairment . Have history presence cardiovascular , respiratory , renal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug constitute risk take study medication interfere interpretation data . Evidence hepatorenal syndrome Spontaneous bacterial peritonitis within 6 month study entry . Variceal bleed within 3 month study entry . Severe hyponatremia ( Na &lt; 120 mmol/L ) . Presence hepatocellular carcinoma . Severe encephalopathy . Hemoglobin &lt; 9.0 g/dL . Platelet count &lt; 50 x 109 cells/L , value &lt; 50 x 109 cells/L may permit discretion investigator consultation sponsor . Concomitant use drug except indicated treatment liver disease related complication . Concomitant use anticoagulant include warfarin . Regular use drug abuse and/or positive finding urinary drug screen except prescribe related complication ( ie , pain , insomnia , anxiety ) liver disease . The use medication know interfere hepatic metabolism ( ie , barbiturate , phenothiazine ) know alter major organ system within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>